AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Hyper IgM Syndrome

Recent research efforts aimed at curing Hyper IgM Syndrome.

Last updated

Hyper IgM Syndrome

Overview

Hyper IgM syndrome is a group of rare inherited immune disorders in which B cells cannot properly “class switch”—the process that lets them make protective antibodies such as IgG and IgA instead of mainly IgM. The best-studied and most severe form, X-linked hyper IgM syndrome type 1 (XHIGM), is caused by harmful variants in CD40LG, which prevent activated CD4 T cells from providing an essential signal to B cells and other immune cells. It predominantly affects males and can cause recurrent bacterial and opportunistic infections, neutropenia, liver disease, autoimmunity, and increased malignancy risk. CD40 Ligand Deficiency (ncbi.nlm.nih.gov)

Current care includes lifelong immunoglobulin replacement, antimicrobial prevention and rapid treatment of infections, management of neutropenia when needed, and surveillance for liver and gastrointestinal complications. For CD40 ligand deficiency, allogeneic hematopoietic stem-cell transplantation (HSCT)—replacement of blood-forming stem cells with donor cells—is currently the only established curative treatment and is preferably undertaken before irreversible organ damage develops. CD40 Ligand Deficiency (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been focused most intensely on XHIGM caused by CD40LG defects, because the disorder is monogenic and because restoring CD40L must be done with tight, activation-dependent control rather than continuous overexpression. The field has progressed from mouse and patient-cell proof-of-concept studies to an NIH first-in-human, single-patient base-editing program; however, durable safety and clinical benefit in more than one patient remain unproven, so an autologous gene-based cure is promising but still experimental. Modeling and optimization of gene editing First-in-human base-edit therapy abstract (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The principal strategy has been precise gene editing: inserting a functional CD40LG sequence into the patient’s own gene so that CD40L is made only when T cells are activated. In a 2021 preclinical study, researchers edited patient-derived CD4 T cells and blood-forming stem/progenitor cells (HSPCs), restored regulated CD40L expression and B-cell helper activity, and showed that functional T-cell transfer improved antibody responses and protection from Pneumocystis infection in an XHIGM mouse model. The authors obtained roughly 25% targeted editing in long-term repopulating human HSPCs and concluded that edited T cells could offer a comparatively rapid route to meaningful immune benefit. Modeling and optimization of gene editing (pmc.ncbi.nlm.nih.gov)

A key advance has been the move from a conventional gene-addition model toward endogenous, or native-control, repair. Simply adding a permanently active CD40LG gene is unsafe because CD40L must be switched on transiently and at the right intensity; unregulated expression caused abnormal lymphoid growth in earlier animal studies. Newer CRISPR-based approaches instead place corrective coding sequence into the first intron of CD40LG, allowing the repaired gene to remain under its natural regulatory system. Genome-integrity assessment of edited T cells (pmc.ncbi.nlm.nih.gov)

A separate 2024 study addressed a major barrier to permanent stem-cell therapy: homology-directed repair (HDR), the DNA-repair process used for precise insertion, is often inefficient in true long-term HSPCs. Adding the DNA-PK inhibitor AZD7648 increased targeted CD40LG HDR to approximately 60% in mobilized peripheral-blood CD34-positive cells and improved persistence of edited cells in primary and secondary mouse xenografts. Edited HSPCs generated T cells with appropriately activation-regulated CD40L expression, supporting their potential as a one-time, durable treatment. DNA-PK inhibition for XHIGM editing (pmc.ncbi.nlm.nih.gov)

The most consequential recent development is patient-specific adenine base editing, which changes a single DNA letter without intentionally creating a double-strand DNA break. In the NIH program, an adenine base editor was designed to correct a CD40LG nonsense variant, c.C>T (p.Gln220Ter), in a 37-year-old man. Preclinical manufacturing studies reported greater than 90% correction in that patient’s HSPCs and T cells, with no significant unintended edits detected by the reported assays. First-in-human base-edit therapy abstract (rupress.org)

Clinical Trials and Experimental Approaches

The notable active clinical effort is NIH protocol 002385 / NCT06959771, a Phase 1/2, single-patient study led by the National Institute of Allergy and Infectious Diseases (NIAID). It uses two autologous products: base-edited HSPCs intended to establish lifelong blood and immune-cell production after busulfan conditioning, followed by base-edited T cells intended as a temporary bridge while edited stem cells generate new immune cells. The listed study completion date is October 28, 2027. NCT06959771 trial record (clinicaltrials.gov)

Preliminary results reported in a May 2026 conference abstract described a clinically complex participant with chronic cryptosporidial infection, liver disease, portal hypertension, and bronchiectasis who lacked an HLA-matched donor. Following worsening liver tests after alemtuzumab, the team delayed conditioning, gave the edited T-cell product, then proceeded with low-dose busulfan and edited-HSPC infusion. At one and two months after treatment, the investigators reported over 90% corrected alleles in myeloid cells, over 60% in natural-killer cells, over 40% in B cells, 27% in T cells, and first detection of class-switched IgG-positive B cells. These are encouraging early signals, but they are conference-abstract data from one person, not yet long-term peer-reviewed evidence of cure. First-in-human base-edit therapy abstract (rupress.org)

Allogeneic HSCT also continues to improve as an established curative approach. A recently reported single-center series using reduced-toxicity conditioning in ten patients with XHIGM who underwent transplantation between 2010 and 2024 reported 88.9% five-year overall survival, though the small retrospective cohort cannot settle which conditioning regimen is best for all patients. Reduced-toxicity HSCT in XHIGM (pubmed.ncbi.nlm.nih.gov)

Methodologies and Scientific Approaches

Researchers are combining patient-derived CD4 T cells, mobilized peripheral-blood CD34-positive HSPCs, XHIGM mouse models, and human-cell xenografts to compare rapid T-cell replacement with potentially permanent stem-cell correction. Common platforms include CRISPR-Cas9 delivered as a ribonucleoprotein, donor DNA delivered by adeno-associated virus serotype 6 or integrase-defective lentiviral vectors, and—most recently—adenine base editors for mutation-specific repair. Immune recovery is assessed through activation-regulated CD40L expression, B-cell class switching, antigen-specific IgG production, resistance to opportunistic infection in animals, and multilineage engraftment. Modeling and optimization of gene editing DNA-PK inhibition for XHIGM editing (pmc.ncbi.nlm.nih.gov)

Safety work has become more sophisticated. A 2023 study used droplet-digital PCR, karyotyping, optical genome mapping, and sequencing to look for large deletions, rearrangements, and unwanted donor-template integration after CRISPR editing of CD4 T cells. It found that large on-target deletions can occur early after editing, but that selection for successfully corrected cells reduced these adverse outcomes; the study also underscored the need for multiple complementary quality-control assays before infusion. Genome-integrity assessment of edited T cells (pmc.ncbi.nlm.nih.gov)

Leading Institutions and Funding

The major preclinical CD40LG-editing program has been led by the San Raffaele Telethon Institute for Gene Therapy and IRCCS San Raffaele Scientific Institute in Milan, with collaborators across Italian and European immunology and transplant centers. The 2023 safety study reports support from Fondazione Telethon’s TIGET Core Grant, the E-Rare-3 Joint Transnational Call program, and Genespire; public reporting in that article does not provide disease-specific award amounts. Genome-integrity assessment of edited T cells (pmc.ncbi.nlm.nih.gov)

In the United States, NIAID and the NIH Clinical Center are leading the first-in-human base-editing effort, with contributions from the NIH Center for Cellular Engineering, the Frederick National Laboratory for Cancer Research, Massachusetts General Hospital, UT Southwestern, and Cellscript/Wisconsin Institute for Immune and Cell Therapy. Seattle Children’s Research Institute has also advanced HSPC-editing optimization, including DNA-PK inhibition to improve precise repair and stem-cell engraftment. First-in-human base-edit therapy abstract DNA-PK inhibition for XHIGM editing (rupress.org)

Strengths, Limitations, and Challenges

The strongest aspect of current work is that it targets the cause of XHIGM while preserving normal CD40L timing and dosage. Autologous editing could avoid donor scarcity, graft-versus-host disease, and donor-cell rejection, while the two-product NIH design may provide functional corrected T cells during the vulnerable period before edited stem cells engraft. The first reported recipient’s early multilineage engraftment and appearance of class-switched B cells provide a biologically meaningful proof-of-concept signal. First-in-human base-edit therapy abstract (rupress.org)

Important limitations remain. The clinical evidence consists of a single, highly individualized treatment with only short follow-up; base editing is mutation-specific, so it may not readily serve all CD40LG variants; and autologous HSPC therapy still requires cell collection, complex manufacturing, conditioning chemotherapy, and specialized follow-up. CRISPR-based HDR approaches also carry risks of large deletions and unintended donor-template integrations, even when edited cells retain function, making long-term clonal monitoring essential. Finally, these CD40LG-focused treatments will not automatically cure every genetic condition that produces a hyper-IgM phenotype. Genome-integrity assessment of edited T cells CD40 Ligand Deficiency (pmc.ncbi.nlm.nih.gov)

Outlook and Future Directions

As of October 18, 2026, Hyper IgM syndrome has an established donor-transplant cure for appropriate patients, while autologous gene editing has entered an early first-in-human stage for one form of XHIGM. The milestones to watch are sustained corrected HSPC engraftment, recovery of normal antibody production and infection control, freedom from serious editing-related or conditioning-related toxicity, and longer-term evidence that the edited immune system remains stable without immunoglobulin replacement. If those milestones are achieved and replicated across patients and mutation types, gene editing could become a donor-independent curative option; it is not yet ready to replace HSCT as standard care. NCT06959771 trial record First-in-human base-edit therapy abstract (clinicaltrials.gov)

References

Don't see your disease? Request a report